


Achaogen
Investor Relations Department
7000 Shoreline Court,
3rd Floor
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO

Last Trade:	10.64
Trade Time:	4:00 PM ET Dec 12, 2017
Change:	-0.67  (5.924%)
Day Range	10.63 - 11.58
52-Week Range	10.24 - 27.79
Volume	964,092

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multi-drug resistant (MDR), gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). In 2013, the Centers for Disease Control and Prevention identified CRE... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 11, 2017*
[Achaogen Appoints Blake Wise Chief Executive Officer](#)
- Nov 30, 2017*
[Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference](#)
- Nov 24, 2017*
[Achaogen Announces New Employment Inducement Grants](#)
- Nov 8, 2017*
[Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- Nov 6, 2017*
[Achaogen to Present at the Stifel 2017 Healthcare Conference](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 26, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)